Latest Current Report
Filed: 2026-05-08
Key Insights
- AlloNK (AB-101) demonstrated strong Phase 2a efficacy data with >50% of refractory RA patients achieving ACR50 response at six months, with 19/21 patients showing clinically meaningful disease reductions by three months, supporting advancement to Phase 3 registrational trials.
- FDA alignment achieved on single Phase 3 registrational trial design for refractory RA enrolling ~150 patients (2:1 randomization to AlloNK+rituximab vs rituximab alone), with ACR50 at six months as primary endpoint, de-risking the regulatory pathway.
- Favorable safety profile demonstrated with zero CRS/ICANS events, no treatment discontinuations due to adverse events, and 2% Grade 3+ infection rate comparable to approved RA therapies, addressing key cell therapy safety concerns.
- Company suspended its ATM (At-The-Market) offering with Leerink Partners, suggesting potential near-term financing needs or strategic capital allocation decisions during clinical advancement phase.
- Clinical trial expansion underway with >70 autoimmune patients treated across multiple indications (RA, Sjögren's disease, systemic sclerosis) at >40 global sites, demonstrating broad autoimmune disease potential beyond initial RA indication.